Cidofovir hydrate | 149394-66-1

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 抗病毒类药
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Cidofovir hydrate
• 英文别名: [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid;hydrate
• CAS: 149394-66-1
• 化学式: C8H16N3O7P
• 分子量: 297.2
• InChiKey: KLJYJZIIJLYJNN-RGMNGODLSA-N

物化性质

• 熔点：
  >250°C (dec.)
• 溶解度：
  DMSO（微溶）、水（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  -2.49
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  147
• 氢给体数：
  5
• 氢受体数：
  7

安全信息

• 海关编码：
  2933599550
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H315,H317,H319,H335

制备方法与用途

应用：用于治疗巨细胞病毒（CMV）感染。

生物活性：Cidofovir是一种注射型的巨细胞病毒（CMV）DNA聚合酶抑制剂。

文献信息

• Liquid protein formulations containing cimetidine
  申请人：Eagle Biologics, Inc.

  公开号：US10646571B2

  公开（公告）日：2020-05-12

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

  目前已开发出浓缩、低粘度、低容量的液体蛋白质药物制剂。这些制剂可以通过皮下注射或肌肉注射快速方便地给药，而不需要长时间的静脉注射。这些制剂包括低分子量和/或高分子量蛋白质（如 mAbs），以及通常为大体积极性有机化合物的降粘剂，如许多 GRAS（美国食品和药物管理局一般认为安全的化合物清单）和非活性注射成分以及美国食品及药物管理局批准的治疗药物。
• Liquid protein formulations containing thiamine pyrophosphate (TPP)
  申请人：EAGLE BIOLOGICS, INC.

  公开号：US10821184B2

  公开（公告）日：2020-11-03

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.

  目前已开发出浓缩、低粘度、低容量的液体蛋白质药物制剂。此类制剂可通过皮下注射或肌肉注射快速方便地给药，而无需长时间静脉注射。这些制剂包括低分子量和/或高分子量蛋白质，如 mAbs 和有机磷。加入一种或多种有机磷后，制剂的粘度会大大降低。
• Liquid Protein Formulations Containing Thiamine
  申请人：Eagle Biologics, Inc.

  公开号：US10849977B2

  公开（公告）日：2020-12-01

  Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.

  目前已开发出浓缩、低粘度、低容量的液体蛋白质药物制剂。这些制剂可以通过皮下注射或肌肉注射快速方便地给药，而不需要长时间的静脉注射。这些制剂包括低分子量和/或高分子量蛋白质（如 mAbs），以及通常为大体积极性有机化合物的降粘剂，如许多 GRAS（美国食品和药物管理局一般认为安全的化合物清单）和非活性注射成分以及美国食品及药物管理局批准的治疗药物。
• LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES
  申请人：Arsia Therapeutics, Inc.

  公开号：EP3043772A1

  公开（公告）日：2016-07-20
• LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS
  申请人：Arsia Therapeutics, Inc.

  公开号：EP3043775A2

  公开（公告）日：2016-07-20